The Business of Anti-Aging Science

de Magalhaes, Joao Pedro ORCID: 0000-0002-6363-2465, Stevens, Michael and Thornton, Daniel ORCID: 0000-0002-4994-2942 (2017) The Business of Anti-Aging Science. TRENDS IN BIOTECHNOLOGY, 35 (11). pp. 1062-1073.

Text aging_business_TrendsBiotech_revised_final.docx - Author Accepted Manuscript Download (175kB)

Abstract

Age-related conditions are the leading causes of death and health-care costs. Reducing the rate of aging would have enormous medical and financial benefits. Myriad genes and pathways are known to regulate aging in model organisms, fostering a new crop of anti-aging companies. Approaches range from drug discovery efforts to big-data methods and direct-to-consumer (DTC) strategies. Challenges and pitfalls of commercialization include reliance on findings from short-lived model organisms, poor biological understanding of aging, and hurdles in performing clinical trials for aging. A large number of potential aging-associated interventions and targets exist, but given the long validation times only a small fraction can be explored for clinical applications. If even one company succeeds, however, the impact will be huge.

Item Type:	Article
Uncontrolled Keywords:	Animals, Humans, Biotechnology, Aging, Biomedical Research
Depositing User:	Symplectic Admin
Date Deposited:	14 Aug 2017 06:44
Last Modified:	19 Jan 2023 06:58
DOI:	10.1016/j.tibtech.2017.07.004
Related URLs:	Author Publisher
URI:	https://livrepository.liverpool.ac.uk/id/eprint/3008938